kabutan

Kubota Pharmaceutical Holdings Co., Ltd.(4596) Summary

4596
TSE Growth
Kubota Pharmaceutical Holdings Co., Ltd.
46
JPY
+1
(+2.22%)
Dec 12, 3:30 pm JST
0.29
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
45.8
Dec 12, 11:51 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.87
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
44 JPY 0.28 USD
Previous Close Dec 11
45 JPY 0.28 USD
High Dec 12, 2:59 pm
47 JPY 0.30 USD
Low Dec 12, 9:00 am
44 JPY 0.28 USD
Volume
957,200
Trading Value
0.04B JPY 0.28M USD
VWAP
45.31 JPY 0.29 USD
Minimum Trading Value
4,600 JPY 29 USD
Market Cap
3.24B JPY 0.02B USD
Number of Trades
188
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
436
1-Year High Sep 3, 2025
18,100
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 3,558,400
Nov 28, 2025 0 3,510,300
Nov 21, 2025 0 3,740,200
Nov 14, 2025 0 4,091,100
Nov 7, 2025 0 4,296,200
Company Profile
Kubota Pharmaceutical Holdings Co., Ltd. is a venture company focused on developing treatments for eye diseases. The company is currently concentrating on developing corrective glasses for myopia. Drug development projects have been suspended.
Sector
Pharmaceuticals
Kubota Pharmaceutical Holdings Co., Ltd. is committed to developing innovative treatments and medical technologies as an ophthalmic medical solutions company. The company aims to contribute to maintaining and restoring vision for patients with eye diseases by developing and commercializing innovative pharmaceuticals and medical devices. Their main focus is in the medical device field, with emphasis on the "Kubota Glass," a wearable device for myopia control using proprietary active stimulation technology. They are also developing "eyeMO," an ultra-compact OCT for home-based ophthalmic care. In the small molecule compound area, they are advancing the development of emixustat hydrochloride as a treatment for Stargardt disease, based on visual cycle modulation technology. The company is actively pursuing partnership strategies with other companies to expand their pipeline and is also exploring M&A opportunities.